Nerve excitability studies in Brown–Vialetto–Van Laere syndrome due to RFVT2 deficiency suggest that an increase in myelin permeability underlies the motor nerve dysfunction.
These abnormalities are partially reversed by riboflavin therapy.
Nerve excitability studies may be further developed in larger cohorts as a potential biomarker to identify treatment response.